CME Group Inc.
CME · Nasdaq
Analyst Consensus
Hold
Analyst Ratings Synthesis
The supplied current consensus is Hold among 16 analysts, with a mean target of $286; low and high targets are unavailable, so the breadth of the target range cannot be measured. Goldman Sachs is the least bullish named firm in the evidence, assigning a Sell rating and a $245 target, while no named analyst is identified as the most bullish. No rating action dated during the stated week is supplied. The latest cited revisions were lower: Barclays cut its target to $270 from $316 and Goldman Sachs to $245 from $267. The substantive disagreement is whether trading and crypto growth can offset concerns about perpetual futures and multiple compression.
- Coinbase vs. CME Group: Which Crypto Stock Is the Better Buy Now?
- Trump Says the Market Is Going to "Go Through the Roof." His Iran Escalation and New Tariffs Suggest Otherwise.
- Fed Chair Kevin Warsh Plays the Hawk But May Have a Dove Up His Sleeve
- CBOE Q2 Earnings Beat on Options Strength, Revenue Outlook Raised
- ICE Q2 Earnings Beat on Data Growth and Mortgage Strength
Rating Actions
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Barclays | — | $270 | -3.9% | Jul 9, 2026 | Open the report this row came from | |
| The Goldman Sachs Group, Inc. | — | $245 | -12.8% | Jun 30, 2026 | Open the report this row came from | |
| Weiss Ratings | — | — | — | Jun 25, 2026 | Open the report this row came from |
Research Reports
- Coinbase vs. CME Group: Which Crypto Stock Is the Better Buy Now?
- CME Group (Nasdaq:CME) - Stock Analysis - Simply Wall St
- CME Maintained by Barclays -- Price Target Lowered to $270
- Weekly Investment Analysts’ Ratings Changes for CME Group (CME)
- CME Group Inc. Stock 12‑Month Price Target Cut to $285.93, Implies 19% Upside
- CME Group (CME) Stock Forecast & Analyst Price Targets
